Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $2.40 billion. The enterprise value is $2.14 billion.
| Market Cap | 2.40B |
| Enterprise Value | 2.14B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 140.40 million shares outstanding. The number of shares has increased by 62.39% in one year.
| Shares Outstanding | 140.40M |
| Shares Change (YoY) | +62.39% |
| Shares Change (QoQ) | +38.85% |
| Owned by Insiders (%) | 4.99% |
| Owned by Institutions (%) | 50.33% |
| Float | 122.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 14.31 |
| PS Ratio | 2.41 |
| Forward PS | 2.61 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.90
| Current Ratio | 0.90 |
| Quick Ratio | 0.64 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.84 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.60% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $645,890 |
| Profits Per Employee | -$258,397 |
| Employee Count | 1,543 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 14.77 |
Taxes
In the past 12 months, Novavax has paid $3.11 million in taxes.
| Income Tax | 3.11M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +108.15% in the last 52 weeks. The beta is 1.97, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | +108.15% |
| 50-Day Moving Average | 14.83 |
| 200-Day Moving Average | 7.64 |
| Relative Strength Index (RSI) | 62.33 |
| Average Volume (20 Days) | 7,551,198 |
Short Selling Information
The latest short interest is 31.40 million, so 22.36% of the outstanding shares have been sold short.
| Short Interest | 31.40M |
| Short Previous Month | 29.53M |
| Short % of Shares Out | 22.36% |
| Short % of Float | 25.64% |
| Short Ratio (days to cover) | 3.68 |
Income Statement
In the last 12 months, Novavax had revenue of $996.61 million and -$398.71 million in losses. Loss per share was -$3.13.
| Revenue | 996.61M |
| Gross Profit | 627.72M |
| Operating Income | -398.57M |
| Pretax Income | -395.60M |
| Net Income | -398.71M |
| EBITDA | -337.06M |
| EBIT | -381.39M |
| Loss Per Share | -$3.13 |
Balance Sheet
The company has $491.04 million in cash and $229.33 million in debt, giving a net cash position of $261.71 million or $1.86 per share.
| Cash & Cash Equivalents | 491.04M |
| Total Debt | 229.33M |
| Net Cash | 261.71M |
| Net Cash Per Share | $1.86 |
| Equity (Book Value) | -867.08M |
| Book Value Per Share | -6.18 |
| Working Capital | -77.26M |
Cash Flow
In the last 12 months, operating cash flow was -$471.93 million and capital expenditures -$42.50 million, giving a free cash flow of -$514.43 million.
| Operating Cash Flow | -471.93M |
| Capital Expenditures | -42.50M |
| Free Cash Flow | -514.43M |
| FCF Per Share | -$3.68 |
Margins
Gross margin is 62.99%, with operating and profit margins of -39.99% and -40.01%.
| Gross Margin | 62.99% |
| Operating Margin | -39.99% |
| Pretax Margin | -39.69% |
| Profit Margin | -40.01% |
| EBITDA Margin | -33.82% |
| EBIT Margin | -38.27% |
| FCF Margin | -51.62% |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.39% |
| Shareholder Yield | -62.39% |
| Earnings Yield | -16.60% |
| FCF Yield | -21.41% |
Analyst Forecast
The average price target for Novavax is $19.00, which is 11.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.00 |
| Price Target Difference | 11.05% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | -2.34% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -4.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.75 |
| Piotroski F-Score | 2 |